



**Press Release 14 December 2007**

## **Medivir to receive two milestone payments amounting to 17 million euros in the Tibotec HCV collaboration**

Medivir (OME: MVIRB SS) is collaborating with Tibotec Pharmaceuticals Ltd to develop HCV NS3/4A Protease Inhibitors for the treatment of chronic hepatitis C virus (HCV) infection.

The drug candidate, TMC435350, recently advanced into phase II of the clinical trial program. The first phase IIa study was initiated in Europe by Tibotec Pharmaceuticals Ltd at the end of November.

Under the terms of the Research Development and License Agreement of November 2004, Medivir are entitled to a number of pre-specified milestone payments. Medivir has achieved one of the clinical milestones in the agreement and has thus secured a milestone payment of five million Euro (around MSEK 47).

The second payment is due because Medivir has opted to decline a contractual opportunity to obtain from Tibotec, at some point in the future, the marketing rights for an approved pharmaceutical in the Nordic countries. In return Tibotec will make a cash payment of 12 million euros (around MSEK 113).

"This will be our largest ever licensing payment. A robust financial position will facilitate the creation of a Nordic sales and marketing organization and strengthen us in coming partnership negotiations. Our goal is to achieve revenues from sales of licensed pharmaceuticals in the Nordic market in the coming 12 months", says Medivir's CEO Lars Adlersson.

### **For additional information, please contact**

Rein Piir, CFO & VP Investor Relations, Medivir +46 8 5468 3123 or +46 708 537 292.

**For more on Medivir, please see the company website: [www.medivir.se](http://www.medivir.se)**